These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2702430)

  • 1. The cost of bilateral orchiectomy as a treatment for prostatic carcinoma.
    McClinton S; Moffat LE; Ludbrook A
    Br J Urol; 1989 Mar; 63(3):309-12. PubMed ID: 2702430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost and availability of therapeutic options in advanced prostatic carcinoma in Turkey.
    Ilker NY; Dillioğlugil O; Akdaş A
    Int Urol Nephrol; 1992; 24(2):155-7. PubMed ID: 1624259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.
    Chon JK; Jacobs SC; Naslund MJ
    J Urol; 2000 Sep; 164(3 Pt 1):735-7. PubMed ID: 10953136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
    Mariani AJ; Glover M; Arita S
    J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced prostate cancer. The role of high priced hormone therapy.
    Nicol DL; Heathcote PS; Kateley GD; Lloyd S
    Med J Aust; 1993 Jul; 159(1):16-9. PubMed ID: 8316105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer.
    Henriksson P; Stege R
    Int J Technol Assess Health Care; 1991; 7(2):220-5. PubMed ID: 1907600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer.
    Bonzani RA; Stricker HJ; Peabody JO; Menon M
    J Urol; 1998 Dec; 160(6 Pt 2):2446-9. PubMed ID: 9817400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.
    Hillner BE; Roberts JD
    J Natl Cancer Inst; 2000 Nov; 92(21):1704-6. PubMed ID: 11058606
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
    Rutqvist LE; Wilking N
    Br J Cancer; 1992 Jun; 65(6):927-9. PubMed ID: 1616866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness comparison of estrogen therapy and orchidectomy in patients with prostatic cancer.
    Henriksson P; Edhag O
    Int J Technol Assess Health Care; 1987; 3(4):523-9. PubMed ID: 10312366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical or surgical treatment of prostatic cancer?].
    Wilking N; Rutqvist LE
    Lakartidningen; 1988 Nov; 85(47):4042, 4047. PubMed ID: 3059111
    [No Abstract]   [Full Text] [Related]  

  • 14. Hospitalisation of prostatic cancer patients undergoing orchiectomy.
    Johansen TE; Fjaere HT
    Br J Urol; 1991 Jul; 68(1):62-6. PubMed ID: 1873693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical or surgical castration in prostatic cancer? Experience of 100 orchiectomies].
    Johansen TE; Fjaere HT
    Tidsskr Nor Laegeforen; 1990 Feb; 110(4):467-9. PubMed ID: 2309193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
    Nygård R; Norum J; Due J
    Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
    Pitts WR
    J Urol; 2001 Aug; 166(2):632. PubMed ID: 11458103
    [No Abstract]   [Full Text] [Related]  

  • 19. Orchiectomy.
    Alfthan O
    Scand J Urol Nephrol Suppl; 1980; 55():117-20. PubMed ID: 6259721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer of the prostate: subcapsular orchiectomy].
    Cukier J; Rivain T
    Bull Cancer; 1985; 72(6):543-8. PubMed ID: 4092105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.